HeartBeam, Inc. expected to post a loss of 9 cents a share - Earnings Preview
HeartBeam, Inc. expected to post a loss of 9 cents a share - Earnings Preview
HeartBeam, Inc. BEAT.OQ BEAT.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2026
The Santa Clara California-based company is expected to report revenue of $80 thousand, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for HeartBeam, Inc. is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for HeartBeam, Inc. is $3.25, about 492.2% above its last closing price of $0.55
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.14 | -0.14 | -0.12 | Beat | 13 |
Dec. 31 2026 | -0.13 | -0.14 | -0.14 | Met | -2.8 |
Sep. 30 2025 | -0.13 | -0.13 | -0.15 | Missed | -16 |
Jun. 30 2025 | -0.18 | -0.16 | -0.15 | Beat | 6.3 |
Mar. 31 2025 | -0.14 | -0.15 | -0.18 | Missed | -20 |
Dec. 31 2024 | -0.19 | -0.19 | -0.18 | Beat | 5.3 |
Sep. 30 2024 | -0.17 | -0.17 | -0.19 | Missed | -8.6 |
Jun. 30 2024 | -0.18 | -0.16 | -0.19 | Missed | -15.2 |
This summary was machine generated August 11 at 21:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance